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Abstract
Objective To investigate the risk of tumours in the central nervous
system among Danish mobile phone subscribers.
Design Nationwide cohort study.
Setting Denmark.
Participants All Danes aged ≥30 and born in Denmark after 1925,
subdivided into subscribers and non-subscribers of mobile phones before
1995.
Main outcome measures Risk of tumours of the central nervous system,
identified from the complete Danish Cancer Register. Sex specific
incidence rate ratios estimated with log linear Poisson regression models
adjusted for age, calendar period, education, and disposable income.
Results 358 403 subscription holders accrued 3.8 million person years.
In the follow-up period 1990-2007, there were 10 729 cases of tumours
of the central nervous system. The risk of such tumours was close to
unity for both men and women. When restricted to individuals with the
longest mobile phone use—that is, ≥13 years of subscription—the
incidence rate ratio was 1.03 (95% confidence interval 0.83 to 1.27) in
men and 0.91 (0.41 to 2.04) in women. Among those with subscriptions
of ≥10 years, ratios were 1.04 (0.85 to 1.26) in men and 1.04 (0.56 to
1.95) in women for glioma and 0.90 (0.57 to 1.42) in men and 0.93 (0.46
to 1.87) in women for meningioma. There was no indication of
dose-response relation either by years since first subscription for a mobile
phone or by anatomical location of the tumour—that is, in regions of the
brain closest to where the handset is usually held to the head.
Conclusions In this update of a large nationwide cohort study of mobile
phone use, there were no increased risks of tumours of the central
nervous system, providing little evidence for a causal association.
Introduction
Thenumberofmobilephoneusersisconstantlyincreasingwith
more than five billion subscriptions worldwide in 2010.
1 The
widespread use of mobile phones has led to concerns regarding
potential adverse health effects, particularly tumours of the
central nervous system, of which the brain is the part most
exposed to the radio frequency electromagnetic fields emitted
by an operating mobile phone held to the ear. So far, the
mechanism of potential non-thermal interaction between radio
frequency electromagnetic fields and living systems is
unknown.
2 The results of the Interphone study, the largest
international case-control study on this topic, generally suggest
no increased risk of glioma or meningioma.
3 For glioma,
however, an increased risk (odds ratio 1.40, 95% confidence
interval 1.03 to 1.89) was observed in 364 people with more
than1640hoursofcumulativeuse.Resultsforlongtermmobile
phone users (≥10 years) remain scarce, and all epidemiological
studies are based on few cases.
4 In addition, most studies have
been retrospective case-control studies with self reported data
on mobile phone use, which are prone to bias, particularly
random reporting bias and differential recall bias for cases and
controls, which hampers the risk estimation and precludes firm
conclusions.
5 6
Theonlycohortstudyinvestigatingmobilephoneuseandcancer
to date is a Danish nationwide study comparing cancer risk of
all 420 095 people who had signed a mobile phone contract
with a phone company (subscribers) from 1982 (the year such
phones were introduced in Denmark) until 1995, with the
corresponding risk in the rest of the adult population with
follow-upto1996
7andthen2002.
8Thestudyfoundnoevidence
ofanyincreasedriskofbrainornervoussystemtumoursorany
cancer among mobile phone subscribers. There was, however,
adecreasedrisk(standardisedincidenceratio0.66,0.44to0.95)
ofdevelopingatumourofthebrainornervoussysteminpeople
who had had a subscription for more than 10 years, but this
result was based on only 28 cases.
8 In addition, it was observed
that male mobile phone subscribers were at a lower risk
(standardised incidence ratio 0.88, 0.86 to 0.91) of developing
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Research
RESEARCHtobacco related cancers. Additional investigations showed that
early male subscribers probably constituted a unique subgroup
of people with a higher income and therefore a potentially
distinct risk profile, particularly lower tobacco consumption.
8
We followed up the mobile phone subscriber study to 2007,
with a focus on tumours of the central nervous system. Longer
follow-upincreasedthenumbersofpersonyearsforsubscribers,
particularly in long term subscribers (≥10 years), in whom the
total of person years under risk increased from 170 000 to 1.2
million. This allowed more detailed analysis of long term
subscribers and topographical and morphological subtypes of
intracranial central nervous system tumours. In addition, we
were able to obtain information on socioeconomic status on an
individuallevel,allowingadjustmentforeducationandincome
when estimating risks related to mobile phone use.
Methods
Since 1 April 1968, all Danish residents have been registered
in the central population register. At birth they are assigned a
uniquepersonalidentificationnumberthatisusedinallnational
registers,ensuringaccuratelinkageofinformationamongthese
registers.
9 This system enables researchers to conduct purely
register based cohort studies for exposure data available from
respective registries, as the follow-up of vital status, migration,
and many health outcomes, in particular cancer, can be done by
computerised linkage on an individual level with an exact
calculation of person years at risk. Such a design has been used
tofollowadultpeoplewithamobilephonecontract(subscribers)
for risk of disease compared with the rest of the Danish adult
population; in other words, the whole Danish adult population
was subdivided into subscribers and non-subscribers of mobile
phones and followed up for incidence of cancer and other
diseases.
7 8 10 11
Identification of mobile phone subscribers
The collection of mobile phone subscription records has been
described in detail previously.
7 In brief, 723 421 records for
1982-95 were obtained from the Danish network operators.
Exclusioncriteriaincludedcorporatesubscriptions(n=200507)
and others, as shown in figure 1⇓. In the present analysis
focusing on central nervous system tumours, we left censored
the subscription date of individuals with a subscription before
1987 (1.8% of all subscribers) to 1 January 1987 because
handheld handsets were introduced in Denmark only in 1987
and cranial exposure from car phones (available from 1982) is
muchlowerthanexposurefrommobilephonesheldtothehead.
Cohort definition
In the previous follow-ups of the subscriber study information
on socioeconomic factors was not available on an individual
level, and the comparison of the average income of subscribers
and non-subscribers showed higher average income in the
subscriber group, thereby suggesting potential confounding.
8
To overcome this limitation by obtaining access to individual
data on socioeconomic factors, we conducted our study in the
CANULI (“cancer og social ulighed”) cohort, a register based
Danish cohort study conducted at the Institute of Cancer
Epidemiology on social inequality and cancer.
9 This approach
of restricting the mobile phone study to the CANULI cohort
has been applied previously.
12 The CANULI study included all
Danes born in Denmark in 1925 or later and alive in 1990 who
did not emigrate from the country before 1 January 1990. Entry
into the CANULI cohort was at age 30 because younger people
might have still been in the educational system. Descendants
ofimmigrantswerenotincluded,astheycomprisedasmalland
heterogeneous group, and information on their education, if
acquiredabroad,wasnotsystematicallyrecordedintheregister.
The CANULI cohort is therefore a nationwide cohort of all
Danes aged 30 or older and born after 1925 in Denmark.
Because of the eligibility criteria of CANULI, not all original
members of the mobile phone study were part of CANULI and
therefore the original sample size became somewhat smaller.
We had 3.21 million Danes for follow-up and the number of
themobilephonesubscriberswasreducedby54350individuals
compared with the previous design. We decided that the
advantageofobtainingindividuallevelsocioeconomicdataand
keeping a national representative cohort study clearly
outweighed the seeming disadvantage of a reduction of the still
large sample size.
From the CANULI study we obtained information on highest
attained education and disposable income from the population
based Integrated Database for Labour Market Research
9 from
1990 onwards. Disposable income was calculated from
household income after taxation and the number of people in
the household, deflated according to the 2000 value of the
Danish Crown. Information on cancer diagnosis was available
from the Danish Cancer Register, which provides accurate and
virtually complete nationwide ascertainment of cancers since
1943,includingbenigntumoursofthecentralnervoussystem.
13
CancerswereclassifiedaccordingtoamodifiedDanishversion
of ICD-10 (the international classification of diseases, 10th
revision).
14 Topography and morphology were categorised
according to the first revision (ICD-O1) (until 2003) and third
revision(ICD-O3)(2004-2007)oftheinternationalclassification
ofdiseasesforoncology.
15Dateofbirth,sex,dateofemigration,
or date of death were available for each cohort member from
the Danish central population register.
For the present analysis, follow-up for the occurrence of cancer
started at age 30 or 1 January 1990, whichever occurred later,
and ended on the date of first diagnosis of cancer (except for
non-melanoma skin cancer), date of death, date of emigration,
or 31 December 2007, whichever came first. Figure 2 shows
the definition of the observation periods of collection of
exposure data and follow-up for cancer outcome by age and
calendar time in the study cohort⇓. We excluded from analyses
any people with a history of cancer before entry into the study
(exceptfornon-melanomaskincancer);thisledtotheexclusion
of 3117 subscribers from analyses (370 of whom had cancer
after their first subscription). To reduce the potential for reverse
causation bias—that is, people purchasing a mobile phone
because of early symptoms of their disease—we defined the
person time within the first year of subscription as unexposed
in the analyses. Some 4216 mobile phone subscribers who met
the CANULI eligibility criteria were censored either before
theirfirstsubscription(2660subscribers)orwithinthefirstyear
of subscription (1556 subscribers); they therefore did not
contribute any exposed person time to the study. In the present
analyses, 358 403 people therefore contributed to exposed
person time at risk.
Statistical analysis
We used log linear Poisson regression models to estimate
incidence rate ratios for cancer diagnoses for exposed person
time (in people who had had mobile phone subscriptions for at
least a year) compared with unexposed person time
(non-subscribers or subscribers of less than a year). To
investigateapotentialdose-responserelationbetweenexposure
and outcome, we further categorised the exposed person time
according to years since first subscription, as in our previous
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RESEARCHanalyses and most of the case-control studies (1-4, 5-9, ≥10
years of subscription).
3 7 8 When the number of cases allowed
it, we subdivided the ≥10 years category into 10-12 years and
≥13 years to allow a separate investigation of an even longer
period.
All analyses were stratified by sex and adjusted for age in five
year age groups (30-34, 35-40, etc, to ≥75) and by calendar
period(1990-5,1996-2002,2003-7)(basicmodel).Additionally,
we adjusted analyses for highest attained education (basic
school/high school, vocational training, higher education,
unknown (3.7%)) and disposable income (lowest (1st quarter),
middle (2nd-3rd quarter), highest (4th quarter), and unknown
(4.1%)) (fully adjusted model). In the results, we have shown
only the fully adjusted models, unless the results for basic and
fully adjusted models differed substantially. All covariates and
exposurevariableswereincludedcategorically,andpeoplewere
allowed to change between category levels over time.
Welookedatallcancerscombined(ICD-10C00-D48),cancers
related to smoking (as this group has shown a reduced risk in
previous follow-ups; ICD-10 C09-16, C22, C25, C32-34, C39,
C53,C64,C67,D09.0,D30.3,D41.4),
7 8and,mostimportantly,
the group of tumours of the central nervous system (including
benign tumours) because of exposure of the brain when the
phone is held to the head (ICD-10 C70-72, C75, D32-33, D35,
D42, D44). We separately investigated intracranial tumours
categorised according to ICD-O morphology and topography
codes (glioma, meningioma, and others/unspecified). Among
gliomas, we separately examined the different anatomical sites
to investigate whether the risk is highest for the temporal lobe
with highest absorption of energy emitted from a mobile phone
held to the ear.
16 All anatomical sites with less than 10 exposed
cases and the groups without specification of the topography
(C71.8 (overlapping lesion of brain) and C71.9 (brain,
unspecified)) were classified into the group “other and
unspecified.”Smokingrelatedcancerswereclassifiedaccording
to the system of Olsen et al,
17 covering cancers of the buccal
cavityandpharynx,digestiveorgans,respiratorysystem,urinary
tract, and cervix.
The study was entirely based on record linkage, and therefore
required no personal contact with participants. All statistical
analyses were performed in SAS 9.1.
Results
From 1990 to 2007, 358 403 subscription holders beyond the
first year of subscription accrued 3.8 million person years, with
malesubscribersprovidingnearlyallpersonyears(3.2million).
Duringfollow-up,122302casesofcanceroccurredinmenand
133 713 in women (table 1⇓); in 5111 men and 5618 women
these were tumours of the central nervous system.
The incidence rate ratio for all cancers was slightly decreased
in men (incidence rate ratio 0.96, 95% confidence interval 0.95
to 0.98) but not in women (1.02, 0.98 to 1.06). When we
restricted the outcome to smoking related cancers, the estimate
in men was decreased (0.93, 0.90 to 0.96), decreasing to 0.87
(0.81 to 0.93) in people with 13 or more years of subscription.
Further analyses showed that the decreased incidence rate ratio
for smoking related cancers was restricted to men with basic or
vocational training (0.91, 0.89 to 0.94). In the higher education
group (men with >12 years of education), the association
between mobile phone use and smoking related cancers was
close to unity (1.01, 0.93 to 1.09), strongly suggesting a lack of
confounding by smoking in this subgroup. For tumours of the
centralnervoussystem,theincidencerateratiowasconsistently
close to 1 in women and men, both overall and when stratified
by years since first subscription, and also when restricted to
men in the highest education group (table 1).
Analyses by morphological subtype of intracranial central
nervous system tumours found a slightly but non-significantly
increased incidence rate ratio for glioma in men (1.08, 0.96 to
1.22). The incidence rate ratio was highest in the shortest term
users (1-4 years: 1.20, 0.96 to 1.22), and beyond five years of
use numbers were only slightly raised, and there was no
dose-responseeffectwithincreasingyearsofsubscription(table
2⇓).Inwomen,therewasnoassociationbetweenmobilephone
subscription and glioma regardless of duration (table 2). For
meningioma, there was a reduction in risk of 22% for male
subscribers, with some variations by years of follow-up but
again no indication of dose-response relation. In women,
numbers were small, but there was no sign of increased
incidence rate ratios for meningioma (1.02, 0.71 to 1.47). With
regard to other and unspecified intracranial tumours of the
central nervous system, estimates were non-significantly
increased in men (incidence rate ratio 1.12, 0.95 to 1.33) and
women (1.19, 0.85 to 1.67), but with no clear indication of a
dose-response effect (table 2).
Furthersubdivisionofgliomasinmenbysite(table3⇓)showed
amarginallyincreasedincidencerateratioforthetemporallobe
(1.13, 0.86 to 1.48; n=65). When we stratified data by duration
of follow-up, the highest estimates were seen in the periods 1-4
and 5-9 years of follow-up (incidence rate ratio 1.35, 0.83 to
2.20, n=18; and 1.31, 0.89 to 1.92, n=29, respectively), but
decreased for subscribers of 10 or more years (0.81, 0.50 to
1.32,n=18).Forothersites,thehighestincidencerateratiowas
found for the occipital lobe (1.47, 0.87 to 2.48, n=18), with the
highest estimate for the shortest time users (1-4 years) (2.50,
1.18 to 5.31, n=8), and a non-significantly increased incidence
rate ratio of 1.36 (0.57 to 3.23, n=6) for subscribers of 10 or
more years. The incidence rate ratio for parietal lobe tumours
was non-significantly decreased (0.73, 0.50 to 1.05, n=33). A
significantly increased estimate was seen for “other and
unspecified” sites (1.35, 1.05 to 1.75, n=77), which persisted
when restricted to ≥10 years of exposure (1.44, 1.00 to 2.06,
n=35). To further investigate this finding, we estimated the
incidence rate ratios for each subgroup separately. The highest
estimatewasfoundforthecerebralventricle(2.58,1.08to6.15)
but was based on only eight cases. Non-significantly increased
incidence rate ratios were found for the unspecific groups
“overlapping lesion of brain” (1.34, 0.92 to 1.95, n=35) and
“brain, unspecified” (1.31, 0.86 to 1.99, n=29) respectively. In
longtermsubscribers(≥10years),incidencerateratiosforthese
groups were 1.48 (0.92 to 2.67, n=13) and 1.62 (1.00 to 2.60,
n=21), respectively.
Discussion
In this second update of a large nationwide cohort of 358 403
mobile phone subscribers in Denmark, we observed no overall
increased risk of tumours of the central nervous system or for
all cancers combined associated with use of mobile phones.
With regard to the major histological subtypes of intracranial
tumours of the central nervous system, there were decreased
risk estimates for meningioma and non-significantly increased
risks for glioma in men only, but there was no increase in risk
estimates with increasing time since first subscription.
Importantly, there was no increase of glioma in the temporal
lobes in long term subscribers, as the temporal lobe has been
described as the region of the brain with highest absorption of
energy emitted from mobile phones.
16
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RESEARCHComparison with previous follow-ups and
other studies
Mostresultsofthepresentstudyarecomparablewiththeresults
of the previous follow-up of mobile phone subscribers up to
2002.
8 That study, however, found a significant reduction in
risk of tumours of the brain and nervous system in long term
subscribers (standardised incidence ratio 0.66, 95% confidence
interval 0.44 to 0.95), based on 28 cases, which was suggested
to be a result of chance. Our present study supports this
interpretation as we also found an incidence rate ratio close to
unity based on 316 cases when we investigated ≥10 years of
exposure. We had sufficiently large numbers to simultaneously
investigate risk by tumour type (especially glioma), duration of
follow-up, and sex. We found no dose-response relation with
regard to years of subscription or to the anatomical site of the
glioma (temporal lobe). With regard to other epidemiological
studies, in 2010 Hardell et al found increased risks for glioma
for both short and long term users.
18 For those who had died,
data on exposure were collected from relatives up to 11 years
after death. No validation of this approach was conducted,
making it impossible to assess the impact of the likely and
potentially large recall bias. Most other studies to date have
found no evidence for an increased risk of glioma in short term
users (≤10 years), and for longer latencies results were limited
by small numbers.
3 4 The largest case-control study to date
(Interphone, including 13 countries) found a significantly
increasedriskofgliomaforthehighesttenthofcumulativetime
that mobile phones were used (call time), but bias and error
prevented a causal interpretation.
3 Regarding meningioma, our
results are consistent with most studies in finding no increased
risk.
4 The risk estimate was even slightly decreased in men,
which was also observed in some other studies.
3 19 The risk in
women was close to unity. Also, population level ecological
studies of central nervous system tumours and incidence rates
for glioma after the introduction of mobile phones rule out
mobilephonesasastrongindependentriskfactor.
20-23Moreover,
results from in vivo and in vitro studies do not provide
convincingevidenceforaneffectofexposuretoradiofrequency
electromagnetic fields at non-thermal intensity levels on
carcinogenicity or genotoxicity, and a potential biological
mechanism has not yet been identified.
2
Strengths and limitations of the study
Our nationwide cohort study with objective register based data
on both exposure and cancer outcome practically eliminates
loss to follow-up, which was only 2.2%, and provides accurate
and virtually complete nationwide ascertainment of cancers.
Comparedwiththefollow-upto2002,
8theadditionalfiveyears
of follow-up increased the number of person years in people
withamobilephonesubscriptionforatleast10yearsbyafactor
of seven (1.2 million versus 170 000 person years). Also, the
number of cases of tumours of the central nervous system in
long term subscribers increased from 28 to 316—that is, by a
factor greater than 10. These marked increases allowed
calculation of more robust estimates and allowed both analyses
ofsubtypesofintracranialtumoursofthecentralnervoussystem
and separate investigation of men and women. A further
improvement is that we had information on socioeconomic
indicators for each individual, which was not available
previously.
7 8Thisallowedtheidentificationofasubpopulation
that can be expected to be unbiased by smoking. As the results
for central nervous system tumours in this group were similar
to those we found in all men or women (see table 1), this
suggests that smoking or other lifestyle factors represented by
education and income are not confounders.
A limitation of the study is potential misclassification of
exposure. Subscription holders who are not using their phone
will erroneously be classified as exposed and people without a
subscription but still using a mobile phone will erroneously be
classified as unexposed. Because we excluded corporate
subscriptions, mobile phone users who do not have a
subscription in their own name will have been misclassified as
unexposed. Also, as data on mobile phone subscriptions were
available only until 1995, individuals with a subscription in
1996 or later were classified as non-users. No increased risks
for central nervous system tumours or glioma, however, were
found for subscription holders of ≥13 years compared with
non-subscribers, where there is the strongest contrast between
exposedandunexposed.Moreover,weconductedanadditional
analysis restricting follow-up until 31 December 1996, which
minimised misclassification of exposure. Although this
enormously reduced the number of cases, the results were
similar. For example, the incidence rate ratio in men for central
nervous system tumours was 1.07 (95% confidence interval
0.86 to 1.34; n=83), and for glioma it was 1.08 (0.77 to 1.51;
n=36). In addition, using a one year latency for mobile phone
use reduced potential bias from reverse causation.
Another limitation of our study is that the dose- response
analyses are based on years since first subscription and we did
nothaveinformationontheactualamountofmobilephoneuse.
Therefore, we could not examine the risk restricted to the
subgroup of heaviest users. One might assume that the high
costsrelatedtomobilephoneuseduringtheintroductionperiod
might have caused subscribers to refrain from extensive use of
their mobile phones. Interestingly, we found indications that
earlysubscriptionholdersbefore1995wereinfactheavierusers
(basedonoutgoingcalls)comparedwithallsubscriptionholders
intheyears1996-2002.
24Theweeklyaveragelengthofoutgoing
callswas23minutesforsubscribersin1987-95and17minutes
in 1996-2002. In addition, early subscription holders were on
averagemoreexposedtoradiofrequencyelectromagneticfields
fromtheirmobilephonesastheearlyphoneshadahigheroutput
power than newer generation phones.
25 As handheld mobile
phoneswereintroducedonlyin1987andwefocusedoncentral
nervoussystemtumours,assessmentofexposurewasimproved
by left censoring exposure data to 1987, thereby reducing
misclassificationofexposurefromcarphones.Carphoneswere
availableinDenmarkfrom1982butintermsofcranialexposure
to radio frequency electromagnetic fields are several orders of
magnitude lower than handheld mobile phones. We did not,
however,haveinformationontheuseofcordlessphones,which
operate in a similar frequency range to mobile phones, or on
the use of hands-free kits, with which exposure to the head and
therefore the brain is greatly reduced.
26 Misclassification of
exposure in this study is likely to be non-differential, leading
to a dilution of effects, whereas in the existing case-control
studies there are biases that inflate or deflate effect estimates,
which severely limits the interpretation of the findings.
5 6 In
addition, a validation study using self reported mobile phone
use from 822 people in the control group in the Danish
Interphone study showed that subscription holders were about
four times more likely to report regular mobile phone use
(defined as making or receiving at least one call a week over a
period of six months or more) before 1996 compared with the
general Danish population.
8 Moreover, the results of this
validation study confirmed that our approach to classifying
exposure is appropriate to show or rule out moderate or large
risks related to mobile phone use.
11
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RESEARCHWhat is already known on this topic
Results from epidemiological studies on the association between mobile phone use and the risk of tumours of the central nervous system
are inconclusive, particularly regarding long term use
Previous mainly case-control studies included small numbers of long term users and were prone to error and bias
What this study adds
This large population based cohort study uses data from existing registers and virtually eliminates participation and recall bias associated
with previous studies
There was no association between tumours of the central nervous system or brain and long term (≥10 years) use of mobile phones
Conclusions and outlook
In conclusion, in this update of a nationwide study of mobile
phone subscribers in Denmark we found no indication of an
increased risk of tumours of the central nervous system. The
extended follow-up allowed us to investigate effects in people
whohadusedmobilephonesfor10yearsormore,andthislong
term use was not associated with higher risks of cancer.
Furthermore, we found no increased risk in temporal glioma,
which would be the most plausible tumour location if mobile
phone use was a risk. As a small to moderate increase in risk
for subgroups of heavy users or after even longer induction
periods than 10-15 years cannot be ruled out, however, further
studies with large study populations, where the potential for
misclassification of exposure and selection bias is minimised,
are warranted.
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RESEARCHTables
Table 1| Overall incidence rate ratios (95% confidence intervals) for all cancers, smoking related cancers, and tumours of central nervous
system among mobile phone subscribers in Denmark, 1987-95, followed up to 31 December 2007, for men, women, and men with more
than 12 years of education
Men with >12 years of education‡ Women† Men*
Site of cancer Incidence rate ratio§ Cases Incidence rate ratio§ Cases Incidence rate ratio§ Cases
All cancers¶
1 17 063 1 130 918 1 107 840 Non-subscribers
1.02 (0.97 to 1.06) 2402 1.02 (0.98 to 1.06) 2795 0.96 (0.95 to 0.98) 14 462 Subscribers
Years of subscription:
1.06 (0.97 to 1.16) 482 1.02 (0.95 to 1.10) 717 0.96 (0.92 to 1.00) 2855 1-4
1.00 (0.94 to 1.07) 890 1.03 (0.97 to 1.09) 1203 0.93 (0.91 to 0.96) 5291 5-9
1.01 (0.95 to 1.08) 1030 1.00 (0.93 to 1.06) 875 0.99 (0.97 to 1.02) 6316 ≥10
0.99 (0.91 to 1.07) 647 0.99 (0.92 to 1.07) 721 0.99 (0.96 to 1.02) 4033 10-12
1.04 (0.94 to 1.16) 383 1.00 (0.85 to 1.17) 154 1.00 (0.96 to 1.04) 2283 ≥13
All smoking related sites**
1 5449 1 33 175 1 44 247 Non-subscribers
1.01 (0.93 to 1.09) 731 1.06 (0.98 to 1.14) 685 0.93 (0.90 to 0.96) 5422 Subscribers
Years of subscription:
1.04 (0.88 to 1.23) 152 1.17 (1.02 to 1.36) 185 0.93 (0.87 to 0.99) 1118 1-4
1.05 (0.93 to 1.18) 285 1.06 (0.95 to 1.19) 292 0.93 (0.89 to 0.97) 2041 5-9
0.95 (0.85 to 1.08) 294 0.97 (0.85 to 1.12) 208 0.93 (0.89 to 0.97) 2263 ≥10
1.02 (0.88 to 1.17) 199 0.94 (0.80 to 1.09) 165 0.97 (0.92 to 1.02) 1495 10-12
0.85 (0.69 to 1.04) 95 1.15 (0.85 to 1.55) 43 0.87 (0.81 to 0.93) 768 ≥13
Central nervous system††
1 850 1 5486 1 4397 Non-subscribers
1.00 (0.83 to 1.22) 120 1.02 (0.86 to 1.22) 132 1.02 (0.94 to 1.10) 714 Subscribers
Years of subscription:
1.29 (0.92 to 1.79) 38 0.97 (0.69 to 1.36) 34 1.07 (0.92 to 1.24) 180 1-4
0.95 (0.70 to 1.29) 44 1.05 (0.81 to 1.37) 58 0.95 (0.83 to 1.08) 258 5-9
0.86 (0.62 to 1.20) 38 1.03 (0.75 to 1.40) 40 1.06 (0.94 to 1.20) 276 ≥10
0.82 (0.55 to 1.24) 24 1.05 (0.75 to 1.47) 34 1.08 (0.93 to 1.25) 187 10-12
0.94 (0.55 to 1.60) 14 0.91 (0.41 to 2.04) 6 1.03 (0.83 to 1.27) 89 ≥13
*Men: 18 829 804 person years for non-subscribers, 3 229 589 person years for subscribers (person years by years of subscription: 1-4=893 248, 5-9=1 284 238,
≥10=1 052 103, 10-12: 747 444, ≥13=304 659).
†Women: 21 304 186 person years for non-subscribers, 533 733 person years for subscribers (person years by years of subscription: 1-4=164 507, 5-9=225 864,
≥10=143 361, 10-12=121 529, ≥13=21 832).
‡Subgroup: 3 645 725 person years for non-subscribers, 503 162 person years for subscribers (person years by years of subscription: 1-4=145 818, 5-9=197 710,
≥10=159 634, 10-12=111 053, ≥13=48 582).
§Adjusted for age, calendar period, level of education, and disposable income.
¶ICD-10 codes C00-D48.
**ICD-10 codes C09-16, C22, C25, C32-34, C39, C53, C64, C67, D09.0, D30.3, D41.4.
††ICD-10 codes C70-72, C75, D32-33, D35, D42, D44.
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RESEARCHTable 2| Incidence rate ratios (95% confidence intervals) for intracranial tumours of central nervous system categorised according to ICD-O
morphology and topography codes among men and women with mobile phone subscriptions in Denmark, 1987-95, followed up to 31
December 2007
Women* Men*
Tumour category Incidence rate ratio† Cases Incidence rate ratio† Cases
Glioma‡
1 1455 1 1853 Non-subscribers
0.98 (0.69 to 1.40) 32 1.08 (0.96 to 1.22) 324 Subscribers
Years of subscription:
0.87 (0.43 to 1.75) 8 1.20 (0.96 to 1.50) 85 1-4
1.02 (0.60 to 1.72) 14 1.05 (0.87 to 1.26) 122 5-9
1.04 (0.56 to 1.95) 10 1.04 (0.85 to 1.26) 117 ≥10
— NA 1.06 (0.85 to 1.34) 80 10-12
— NA 0.98 (0.70 to 1.36) 37 ≥13
Meningioma§
1 1248 1 429 Non-subscribers
1.02 (0.71 to 1.47) 30 0.78 (0.58 to 1.05) 50 Subscribers
Years of subscription:
1.08 (0.56 to 2.09) 9 0.92 (0.55 to 1.56) 15 1-4
1.04 (0.60 to 1.79) 13 0.56 (0.33 to 0.96) 14 5-9
0.93 (0.46 to 1.87) 8 0.90 (0.57 to 1.42) 21 ≥10
Other and unspecified¶
1 1297 1 968 Non-subscribers
1.19 (0.85 to 1.67) 35 1.12 (0.95 to 1.33) 162 Subscribers
Years of subscription:
0.95 (0.45 to 2.00) 7 1.09 (0.78 to 1.53) 37 1-4
1.28 (0.78 to 2.09) 16 1.08 (0.83 to 1.40) 60 5-9
1.27 (0.72 to 2.25) 12 1.19 (0.92 to 1.55) 65 ≥10
NA=not applicable (numbers too small for analyses).
*See table 1 for person years for men and women.
†Adjusted for age, calendar period, level of education, and disposable income.
‡ICD-O topography codes C71.0-71.9 and morphology codes 93803-94813.
§ICD-O topography codes C70 and morphology codes 93803-94813.
¶Pineal gland (C75.3) and other morphologies for C70 and C71.0-9.
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RESEARCHTable3|Incidencerateratios(95%confidenceintervals)forgliomasbyanatomicalsiteamongmalemobilephonesubscribers*inDenmark,
1987-95, followed up to 31 December 2007
Incidence rate ratio† Cases Site (code)
Cerebrum (C71.0)
1 375 Non-subscribers
0.90 (0.67 to 1.22) 52 Subscribers
Frontal lobe (C71.1)
1 431 Non-subscribers
1.13 (0.89 to 1.45) 79 Subscribers
Temporal lobe (C71.2)
1 363 Non-subscribers
1.13 (0.86 to 1.48) 65 Subscribers
Parietal lobe (C71.3)
1 293 Non-subscribers
0.73 (0.50 to 1.05) 33 Subscribers
Occipital lobe (C71.4)
1 81 Non-subscribers
1.47 (0.87 to 2.48) 18 Subscribers
Others and unspecified (C71.5-C71.9)
1 310 Non-subscribers
1.35 (1.05 to 1.75) 77 Subscribers
*See table 1 for person years.
†Adjusted for age, calendar period, level of education, and disposable income.
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RESEARCHFigures
Fig 1 Details of determination of final sample contributing to exposed person time
Fig 2 Definition of study cohort and periods of collection of exposure data and follow-up for cancer outcome by age and
time. Shaded area represents time span for which data on socioeconomic indicators were available for members of CANULI
cohort
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